Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies Jan 13, 2015 6:45pm EST
Aptose Biosciences Announces Appointment of Dr. Erich Platzer to Board of Directors Dec 15, 2014 8:00am EST
Aptose Biosciences Presents APTO-253 Preclinical Data at 56th American Society of Hematology Annual Meeting Dec 09, 2014 8:00am EST
Aptose Biosciences to Present at Oppenheimer & Co. 25th Annual Healthcare Conference Dec 05, 2014 8:00am EST
Aptose Biosciences to Present Preclinical Research Update for APTO-253 at the 56th American Society of Hematology Annual Meeting Dec 03, 2014 8:00am EST
Aptose Biosciences reports results for the four months ended September 30, 2014 Nov 04, 2014 4:00pm EST
Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014 Oct 30, 2014 7:01am EDT
Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO Oct 21, 2014 8:00am EDT
